DekaBank Deutsche Girozentrale
TBPH icon

DekaBank Deutsche Girozentrale’s Theravance Biopharma TBPH Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-59,032
Closed -$623K – 1441
2021
Q4 		$623K Buy
59,032
+7,782
+15% +$67.8K ﹤0.01% 1048
2021
Q3 		$374K Hold
51,250
– – ﹤0.01% 1110
2021
Q2 		$760K Sell
51,250
-15,000
-23% -$282K ﹤0.01% 976
2021
Q1 		$1.36M Hold
66,250
– – ﹤0.01% 813
2020
Q4 		$1.17M Buy
66,250
+31,700
+92% +$569K ﹤0.01% 821
2020
Q3 		$515K Buy
34,550
+25,636
+288% +$480K ﹤0.01% 929
2020
Q2 		$183K Hold
8,914
– – ﹤0.01% 915
2020
Q1 		$203K Buy
+8,914
New +$223K ﹤0.01% 879
2019
Q4 		– Sell
-9,600
Closed -$187K – 1220
2019
Q3 		$187K Sell
9,600
-9,600
-50% -$194K ﹤0.01% 863
2019
Q2 		$306K Buy
19,200
+7,500
+64% +$152K ﹤0.01% 967
2019
Q1 		$337K Buy
11,700
+2,100
+22% +$53.2K ﹤0.01% 979
2018
Q4 		$223K Sell
9,600
-2,100
-18% -$56.7K ﹤0.01% 951
2018
Q3 		$337K Sell
11,700
-300
-3% -$8.18K ﹤0.01% 1001
2018
Q2 		$275K Sell
12,000
-12,000
-50% -$285K ﹤0.01% 1004
2018
Q1 		$563K Sell
24,000
-500
-2% -$13.7K ﹤0.01% 847
2017
Q4 		$662K Hold
24,500
– – 0.01% 771
2017
Q3 		$662K Hold
24,500
– – 0.01% 778
2017
Q2 		$974K Hold
24,500
– – 0.01% 697
2017
Q1 		$890K Sell
24,500
-2,000
-8% -$63.9K 0.01% 630
2016
Q4 		$838K Buy
26,500
+2,000
+8% +$62K 0.01% 571
2016
Q3 		$862K Hold
24,500
– – 0.01% 571
2016
Q2 		$561K Buy
24,500
+8,200
+50% +$177K 0.01% 664
2016
Q1 		$300K Sell
16,300
-2,900
-15% -$47.4K ﹤0.01% 761
2015
Q4 		$317K Buy
19,200
+2,200
+13% +$34.9K ﹤0.01% 789
2015
Q3 		$187K Buy
17,000
+1,300
+8% +$16.6K ﹤0.01% 884
2015
Q2 		$204K Buy
15,700
+600
+4% +$9.3K ﹤0.01% 886
2015
Q1 		$262K Buy
+15,100
New +$277K ﹤0.01% 845

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

DekaBank Deutsche Girozentrale's TBPH Position: Q1 2022 in Review

DekaBank Deutsche Girozentrale sold out of Theravance Biopharma (TBPH) in Q1 2022, closing a stake of 59,032 shares — an estimated $623K sold.

DekaBank Deutsche Girozentrale first reported a position in TBPH in Q1 2015 and held it in 27 quarters. The position peaked at $1.36M in Q1 2021. 121 funds tracked by Wall St. Rank hold TBPH as of Q1 2022.

  • DekaBank Deutsche Girozentrale reported no remaining Theravance Biopharma position as of Q1 2022 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 59,032 Theravance Biopharma shares in Q1 2022, an estimated $623K.
  • DekaBank Deutsche Girozentrale first reported a position in Theravance Biopharma in Q1 2015 and held it in 27 quarters.
  • DekaBank Deutsche Girozentrale's Theravance Biopharma position peaked at $1.36M in Q1 2021.
  • 121 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2022.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2022, filed 28 Apr 2022.